Suppr超能文献

一种新型免疫复合物捕获荧光检测法(ICFA),使用荧光珠和转染细胞特异性识别人类中性粒细胞抗原(HNA)-1a 和 -1b 抗体。

A novel immunocomplex capture fluorescence assay (ICFA) using fluorescent beads and transfected cells for specific identification of human neutrophil antigen (HNA)-1a and -1b antibodies.

机构信息

Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.

GenoDive Pharma Inc., Atsugi, Kanagawa, Japan.

出版信息

Transfusion. 2024 May;64(5):906-918. doi: 10.1111/trf.17813. Epub 2024 Mar 26.

Abstract

BACKGROUND

To identify specific human neutrophil antigen (HNA) antibodies, assays using neutrophils such as monoclonal antibody-specific immobilization of granulocyte antigens (MAIGA) are recommended. However, these assays are limited by labor-intensive neutrophil preparation and varying antigen expression levels.

METHODS

We evaluated a newly developed immunocomplex capture fluorescence assay (ICFA) for identifying HNA-1 antibodies and compared it to MAIGA and LABScreen Multi (LABM), which utilizes recombinant HNA-coated Luminex beads. For ICFA, HNA-1a or HNA-1b transfected cells replaced neutrophils. Cells incubated with serum were lysed, and immune complexes were captured using five CD16 monoclonal antibody-conjugated Luminex beads. Nine antisera with known specificity and 26 samples suspected of containing HNA antibodies were analyzed by ICFA and MAIGA using neutrophils or transfected cells (ICFA-N or ICFA-T, and MAIGA-N or MAIGA-T, respectively).

RESULTS

ICFA-T and MAIGA-N accurately determined the specificity of all antibodies in the nine antiserum samples. The ICFA-T detection limit was 2048-fold for anti-HNA-1a and 256-fold for anti-HNA-1b; the limits of MAIGA-T, MAIGA-N, and LABM were 32-, 4 ~ 64-, and 128-fold for anti-HNA-1a and 64-, 16 ~ 64-, and 32-fold for anti-HNA-1b, respectively. Twelve and 7 of the remaining 26 samples tested negative and positive, respectively, in both ICFA-T and MAIGA-N. Antibody specificity against HNA-1a or HNA-1b determined using ICFA-T agreed with that determined using MAIGA-N and LABM. Another seven samples tested positive in ICFA-T but negative in MAIGA-N.

CONCLUSION

The novel ICFA is highly sensitive and exhibits specificity similar to MAIGA and LABM for detecting HNA-1 antibodies.

摘要

背景

为了鉴定特定的人类中性粒细胞抗原(HNA)抗体,建议使用中性粒细胞进行检测,如单克隆抗体特异性固定粒细胞抗原(MAIGA)检测。然而,这些检测方法受到劳动密集型中性粒细胞制备和抗原表达水平变化的限制。

方法

我们评估了一种新开发的免疫复合物捕获荧光检测法(ICFA),用于鉴定 HNA-1 抗体,并将其与 MAIGA 和 LABScreen Multi(LABM)进行比较,后者利用重组 HNA 包被的 Luminex 珠。对于 ICFA,用转染 HNA-1a 或 HNA-1b 的细胞替代中性粒细胞。孵育血清的细胞被裂解,并用 5 个 CD16 单克隆抗体偶联的 Luminex 珠捕获免疫复合物。用 9 种已知特异性的抗血清和 26 种疑似含有 HNA 抗体的样本通过使用中性粒细胞或转染细胞(ICFA-N 或 ICFA-T,以及 MAIGA-N 或 MAIGA-T)进行 ICFA 和 MAIGA 进行分析。

结果

ICFA-T 和 MAIGA-N 准确地确定了 9 个抗血清样本中所有抗体的特异性。ICFA-T 对抗-HNA-1a 的检测限为 2048 倍,对抗-HNA-1b 的检测限为 256 倍;MAIGA-T、MAIGA-N 和 LABM 对抗-HNA-1a 的检测限分别为 32、464 和 128 倍,对抗-HNA-1b 的检测限分别为 64、1664 和 32 倍。剩余的 26 个样本中的 12 个和 7 个在 ICFA-T 和 MAIGA-N 中均为阴性和阳性。用 ICFA-T 确定的针对 HNA-1a 或 HNA-1b 的抗体特异性与用 MAIGA-N 和 LABM 确定的特异性一致。另外 7 个样本在 ICFA-T 中呈阳性,而在 MAIGA-N 中呈阴性。

结论

新型 ICFA 高度敏感,对 HNA-1 抗体的检测具有与 MAIGA 和 LABM 相似的特异性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验